Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionRAR-related orphan receptor C thymus-specific isoform (RORgamma2) (RORgammaT) inverse agonist
Molecular Target RAR-related orphan receptor C thymus-specific isoform (RORgamma2) (RORgammaT)
Mechanism of ActionRAR-related orphan receptor (ROR) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today